Showing Results for: “diabetes”

American Diabetes Association’s (ADA’s) Chief Scientific, Medical and Mission Officer, William T. Cefalu, MD, will testify before the U.S. House of Representatives Committee on Energy & Commerce’s Oversight and Investigations Subcommittee during their Prices” hearing on Tuesday, April 2, 2019 at 10:30 a.m. Dr. Cefalu will address the rising costs of insulin, which impact millions of Americans with diabetes who rely on this life-sustaining medication. Dr. Cefalu will share the ADA’s extensive efforts during the past five years to understand and address the issue of rising insulin costs, the

Affordable Care Act’s Medicaid Expansion improves care for people with diabetic foot ulcerations Research presented today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions shows the Affordable Care Act’s Medicaid Expansion appears to have substantial positive effects on the care of racial and ethnic minorities with diabetic foot ulcerations (DFUs). A study entitled “The Affordable Care Act Medicaid Expansion Correlated with Reduction in Lower Extremity Amputation among Minorities with Diabetic Foot Ulcerations,” found a 17% decrease in the risks of amputation

A new consensus report from the American Diabetes Association® (ADA) released today provides critical guidance on the use of continuous glucose monitoring (CGM) systems in hospitals. CGM devices are worn on the body and continuously monitor glucose (sugar) levels, some providing alerts when they go too high or low. The report covers the benefits of CGM systems for hospitalized populations, safety considerations, staff training, and integration with hospital systems. It emphasizes the need for clear protocols, staff education, and proper treatment facility infrastructure to ensure effective

Currently, Ohio state employees have access to Food and Drug Administration (FDA)-approved GLP-1-based medications to treat obesity and prevent diabetes. However, as of July 1, the state has announced it will eliminate coverage of GLP-1 therapies for obesity treatment. “Ending any form of coverage for this life-changing medication would disrupt care and could lead to rebound weight gain and associated health conditions, putting patients at risk for ongoing costly and preventable illnesses, including type 2 diabetes,” said Gary Dougherty, state government affairs director for the American

The American Diabetes Association ® (ADA) applauds the work of the Congressional Diabetes Caucus co-chairs — Sens. Jeanne Shaheen (D-NH) and Susan Collins (R-ME) and Reps. Diana DeGette (D-CO) and Tom Reed (R-NY) — for their work on behalf of the 37 million Americans with diabetes, and we strongly support their proposal to reduce the cost of insulin. The ADA has endorsed the reforms to insulin rebates included in the Insulin Price Reduction Act and a $35 monthly cap on out-of-pocket costs to patients for insulin, both of which are included in the bipartisan package announced today. The

VERTIS-CV trial of SGLT2 inhibitor evaluated medication’s cardiovascular safety in patients with type 2 diabetes and heart disease The sodium glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin does not impact the likelihood of heart attack, stroke, or cardiac death in patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease, according to data presented today. Research also showed the rate of hospitalization for heart failure was lower among study participants treated with ertugliflozin. The study was highlighted during the “Results of the eValuation of

New polling released today by the American Diabetes Association ® (ADA) finds that among respondents who rely on insulin, 72% report paying more than $35 per month, and nearly 40% pay more than $150 monthly. Cost is a more pronounced problem among middle-class Americans with diabetes—44% of insulin-dependent individuals who make between $50,000 and $75,000 per year report paying more than $150 for insulin each month, and this is true for 55% of people who make between $75,000 and $99,000. It’s no surprise, then, that 76% of survey respondents across political parties support a $35 limit on

The Centers for Medicare and Medicaid Services (CMS) has announced it will allow Medicare Part D prescription drug plans to cover insulins with a $35 monthly co-payment throughout the plan year. Generally, Medicare Part D plan coverage has different phases, including a deductible, the donut hole and catastrophic coverage. Under this new option, Medicare enrollees with diabetes will pay $35 per each 30-day supply of a covered insulin prescription until they reach the catastrophic coverage phase, during which they will pay 5% co-insurance. Insulins covered by participating plans will not be

American Diabetes Association®, AARP Foundation, others file brief to defend against Alabama state appeal that would put vulnerable voters at risk during pandemic. Several leading national advocacy groups, including the American Diabetes Association (ADA), the nation’s leading organization for all people living with diabetes, AARP and AARP Foundation, filed an amicus brief today in the U.S. Supreme Court to help defend the rights of older Alabama voters and those with chronic illnesses, such as diabetes. This follows a historic federal court ruling in Alabama earlier this month prioritizing

Today, the Obesity Association™, a division of the American Diabetes Association ® (Obesity Association), announced the publication of the next section in the Standards of Care in Overweight and Obesity . “ Pharmacologic Treatment of Obesity in Adults” is published in the inaugural edition of Diabetes, Obesity, and Cardiometabolic CARE ® and in BMJ Open Diabetes Research & Care. “The establishment of the Obesity Association, and now its associated journal, marks a significant advancement toward a future where the management of cardiometabolic diseases is unified, proactive, and grounded in a